Core Insights - The 8th China International Import Expo (CIIE) highlights Johnson & Johnson's evolution from a first-time exhibitor to a long-term partner in China's healthcare industry, showcasing over 1,000 innovative products over the years [1][5] - Johnson & Johnson is focusing on three main areas: surgery, cardiology, and ophthalmology, aligning its strategy with global objectives while emphasizing local partnerships and innovation [2][5] Group 1: Johnson & Johnson's Participation in CIIE - Johnson & Johnson has showcased over 1,000 innovative products at CIIE, including hundreds of products making their global debut [5] - The company emphasizes a shift from solely importing products to collaborating with local enterprises, integrating into China's innovation ecosystem [1][5] - The CIIE serves as a vital platform for accelerating the commercialization of innovative products, with a focus on high-quality healthcare solutions [6][7] Group 2: Strategic Partnerships and Market Dynamics - The Chinese medical device market is undergoing structural changes, with local innovation gaining momentum and cross-border collaborations becoming essential for success [7][10] - Johnson & Johnson's partnerships with local companies, such as the collaboration with RuLong Surgical, exemplify the shift from competition to strategic cooperation [8][10] - The company aims to leverage local expertise and resources to enhance product reliability and brand reputation while accessing global commercialization networks [10][11] Group 3: Future Opportunities and Challenges - The aging population and increasing demand for high-quality healthcare services present significant opportunities for growth in China's healthcare market [12] - Johnson & Johnson is committed to deep localization and open innovation, recognizing that the era of one-way technology transfer has ended [12] - The company plans to introduce a series of digital healthcare products, reflecting China's strong performance in digitalization [12]

Core Insights - Johnson & Johnson views the China International Import Expo as a strategic platform for promoting innovation and collaboration in the healthcare sector [1][3] Group 1: Product Innovations - Johnson & Johnson showcased over 100 innovative products across its medical technology and innovative pharmaceuticals sectors, with more than ten products making their debut [3] - The ETHICON™ 4000 3D stapler made its Asian debut, featuring a global first 3D stapling technology that enhances tissue alignment and closure integrity compared to traditional methods [3] - The CEREGLIDE™ 71 distal access catheter, also making its Asian debut, offers superior performance for establishing pathways in the neurovascular system, crucial for stroke patients [3] Group 2: Strategic Collaborations - The company introduced the first "Made in China" ultrasonic scalpel, HARMONIC® 7s, and a laparoscopic surgical robot in collaboration with local company Ruijlong Surgical [4] - Johnson & Johnson emphasizes the importance of the Import Expo in accelerating the introduction of global innovations to China and promoting "Made in China" products globally [4] Group 3: Market Engagement - The company aims to leverage the Import Expo to share innovative healthcare solutions and contribute to the development of a "Healthy China" [4] - Johnson & Johnson's innovative pharmaceuticals division highlights the Import Expo as a fast track for innovative treatment solutions to reach patients, reinforcing its commitment to the Chinese healthcare ecosystem [4]

以超声刀HARMONIC®7s为例，该产品由强生医疗科技苏州产业园生产，现已完成10万把的工厂下 线。"这是一个非常好的例证，表明我们'在中国，为中国'的本土化项目是可以取得成功的。"欧礼文 说。 中新社上海11月6日电 (记者钟升)强生医疗科技中国区外科事业部总经理欧礼文6日在第八届中国国际进 口博览会上接受中新社记者专访时表示，强生持续深化本土化战略，提升端到端的本土化能力，并根据 中国本土的需求开展自主研发，迈向"在中国，为世界"。 进博会首日，强生的ETHICON4000腔镜吻合器在中国正式获批，成为进博会"零时差首发新品"，这也 是进博会"全勤生"强生的"亚洲首发"。在强生"进博首秀"的两款外科产品中，HARMONIC®7s超声刀完 全实现中国本土化生产，海山一®腔镜手术机器人则是强生加速本土合作由合作伙伴瑞龙外科带来的首 秀。 欧礼文认为，连续八年参展，进博会的平台效应加快了强生"展品变商品"的进程，助力强生端到端本土 化的加速。进博会的强生展台上，从以往的展品完全海外进口变成如今"中国智造"的展品种类稳步增 加。 在与欧礼文的交流中，"枢纽"一词的出现频率颇高。在欧礼文看来，中国正成为全球医疗科 ...

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 暂定议程 报名：首届全球心血管大会 | 奖项报名倒计时 报名：首届全球骨科大会 | 奖项报名倒计时 2025年3月15日上午，2025中国医学装备大会在重庆悦来国际会议中心成功召开。相关政府部门领导、知名院士、医疗机构专家，研发生产企业、高校、科 研院所、投融资机构负责人等嘉宾出席大会。 中国医学装备协会理事长 侯岩介绍， 2024年中国医学装备市场规模达到 1.35万亿 元，同比增长 6％ 左右 。据了解，目前我国已形成22个大类1100多个 品类的产品体系，是世界上产品类别和品种最齐全的国家之一，产品广泛服务于临床应用，覆盖卫生健康各个领域。 目前大会已圆满落幕。本届展会中，哪些企业凭借创新亮相引起了行业关注？又有哪些前沿产品和技术成为焦点？思宇将全面回顾展会精彩亮点，供各位读 者参考。 # 美敦力 美敦力在本届大会上展出 近80款 全球创新产品， 包括 全球首发的PulseSelect一次性心脏脉冲场消融导管 ，以及多款前沿技术产品， 其中不乏首次展出及近 期获批的产品和技术。 其中包括中国首款获批的 PulseSelect一次性心脏 ...